55,100 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by Swedbank AB
Swedbank AB disclosed a new position in Olema Pharmaceuticals (NASDAQ:OLMA), buying 55,100 shares for about $1.38 million in Q4, raising its stake to 0.08%. Other filings show Jennison Associates, Kingdon Capital, Ameriprise, Candriam and Vanguard also adjusted holdings. Olema reported Q1 EPS of -$0.52 on May 12.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the incremental ownership signal (Swedbank AB and other funds adding) combined with insider selling; however, there is no new OP-1250/OPERA-01 clinical outcome or guidance change to re-rate fundamentals.
Market read
Ownership-flow headlines can move thinly traded biotech names, but without a new trial/earnings catalyst the effect is likely tactical rather than fundamental.
What to watch
The article highlights very high beta (2.05) and large moving-average gaps; technical mean reversion could dominate any flow-driven narrative.
Background
The piece summarizes institutional ownership changes (SEC/13F disclosures) and an insider sale for Olema Pharmaceuticals, plus basic trading/valuation and prior earnings context.
Ticker impact
Swedbank AB disclosed a new 55,100-share position in Olema Pharmaceuticals, alongside other institutional adds and an insider sale.
Near-term trading likely choppy: institutional flows may support, while insider selling and volatile biotech beta can cap follow-through.
The only fresh, company-specific facts here are ownership/flow changes (13F/SEC disclosure) and an insider Form 4 sale; no new clinical or financial datapoint is provided.
Market effects
Adds to a clinical-stage women’s oncology name can marginally influence sentiment toward small-cap biotech risk, but no sector-wide catalyst is cited.
Limited; Swedbank AB is Swedish, but the flow is into a US-listed biotech with no stated cross-border operational impact.
Low; the news is primarily portfolio/ownership positioning rather than a global clinical or regulatory development.
Counterpoint
Institutional “new position” via 13F can reflect rebalancing or passive allocation rather than a conviction catalyst, so price follow-through may fade.
Key entities
- public_companyOlema Pharmaceuticals, Inc.
Clinical-stage biopharma focused on ER-targeting therapies; subject of the institutional ownership and insider activity described.
- institutional_investorSwedbank AB
Disclosed a new position of 55,100 shares in OLMA via its most recent SEC filing.
- insiderShawnte Mitchell
Sold 25,000 shares at an average price of $24.25 (insider transaction disclosed in an SEC filing).
